Ketoconazol CF

Ketoconazol CF may be available in the countries listed below.

Ingredient matches for Ketoconazol CF

Ketoconazole

Ketoconazole is reported as an ingredient of Ketoconazol CF in the following countries:

• Netherlands

International Drug Name Search

Elestrin

Elestrin is a brand name of estradiol, approved by the FDA in the following formulation(s):

ELESTRIN (estradiol - gel, metered; transdermal)

• 
  Manufacturer: AZUR PHARMA II
  
  Approval date: December 15, 2006
  
  Strength(s): 0.06% (0.87GM/ACTIVATION) ^[RLD]

Has a generic version of Elestrin been approved?

No. There is currently no therapeutically equivalent version of Elestrin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elestrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Formulations for transdermal or transmucosal application
  Patent 7,198,801
  Issued: April 3, 2007
  Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
  Assignee(s): Antares Pharma IPL AG
  The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
  
  Patent expiration dates:
  
  
  • June 25, 2022
    
    ✓ 
    Drug product
  
  



• 
  Formulations for transdermal or transmucosal application
  Patent 7,470,433
  Issued: December 30, 2008
  Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
  Assignee(s): Antares Pharma IPL AG
  The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
  
  Patent expiration dates:
  
  
  • August 3, 2021
    
    ✓ 
    Drug product
  
  

See also...

• Elestrin Consumer Information (Drugs.com)
• Elestrin Gel Consumer Information (Wolters Kluwer)
• Elestrin Pump for use on skin Consumer Information (Cerner Multum)
• Elestrin for use on skin Consumer Information (Cerner Multum)
• Estradiol Consumer Information (Drugs.com)
• Estradiol Consumer Information (Wolters Kluwer)
• Estradiol Acetate Consumer Information (Wolters Kluwer)
• Estradiol Cypionate Consumer Information (Wolters Kluwer)
• Estradiol Gel Consumer Information (Wolters Kluwer)
• Estradiol Gel Packets Consumer Information (Wolters Kluwer)
• Estradiol Patch Consumer Information (Wolters Kluwer)
• Estradiol Ring Consumer Information (Wolters Kluwer)
• Estradiol Spray Consumer Information (Wolters Kluwer)
• Estradiol Valerate Consumer Information (Wolters Kluwer)
• Estradiol Weekly Patch Consumer Information (Wolters Kluwer)
• Estring Ring Consumer Information (Wolters Kluwer)
• Estradiol injection Consumer Information (Cerner Multum)
• Estradiol oral Consumer Information (Cerner Multum)
• Estradiol topical for use on skin Consumer Information (Cerner Multum)
• Estradiol transdermal Consumer Information (Cerner Multum)
• Estradiol vaginal Consumer Information (Cerner Multum)
• Estradiol AHFS DI Monographs (ASHP)

Oikamid

Oikamid may be available in the countries listed below.

Ingredient matches for Oikamid

Piracetam

Piracetam is reported as an ingredient of Oikamid in the following countries:

• Bosnia & Herzegowina


• Croatia (Hrvatska)


• Czech Republic


• Serbia


• Slovakia

International Drug Name Search

Imitrex

See also: Generic Imitrex Statdose

Imitrex is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

IMITREX (sumatriptan succinate - injectable; subcutaneous)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 28, 1992
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[RLD][AP]

IMITREX (sumatriptan succinate - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 1, 1995
  
  Strength(s): EQ 100MG BASE ^[RLD][AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Has a generic version of Imitrex been approved?

Yes. The following products are equivalent to Imitrex:

sumatriptan succinate injectable; subcutaneous

• 
  Manufacturer: APP PHARMS
  
  Approval date: March 2, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: APP PHARMS
  
  Approval date: September 18, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: BEDFORD
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: BEDFORD LABS
  
  Approval date: August 11, 2010
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: JHP PHARMS
  
  Approval date: July 9, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: PAR PHARM
  
  Approval date: October 9, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: SAGENT STRIDES
  
  Approval date: June 10, 2010
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: SAGENT STRIDES
  
  Approval date: July 28, 2010
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: TEVA PARENTERAL
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

sumatriptan succinate tablet; oral

• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: DR REDDYS LABS INC
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: November 2, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: ORCHID HLTHCARE
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: February 9, 2009
  
  Strength(s): EQ 100MG BASE ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: SUN PHARM INDS
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: February 9, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imitrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Imitrex.

See also...

• Imitrex Consumer Information (Drugs.com)
• Imitrex Consumer Information (Wolters Kluwer)
• Imitrex Spray Consumer Information (Wolters Kluwer)
• Imitrex Tablets Consumer Information (Wolters Kluwer)
• Imitrex injection Consumer Information (Cerner Multum)
• Imitrex oral/nasal Consumer Information (Cerner Multum)
• Imitrex Advanced Consumer Information (Micromedex)
• Imitrex Oral Advanced Consumer Information (Micromedex)
• Imitrex Subcutaneous Advanced Consumer Information (Micromedex)
• Imitrex AHFS DI Monographs (ASHP)
• Sumatriptan Consumer Information (Wolters Kluwer)
• Sumatriptan Spray Consumer Information (Wolters Kluwer)
• Sumatriptan Tablets Consumer Information (Wolters Kluwer)
• Sumatriptan injection Consumer Information (Cerner Multum)
• Sumatriptan oral/nasal Consumer Information (Cerner Multum)
• Imitrex Stat Dose Refill Advanced Consumer Information (Micromedex)
• Imitrex Stat Dose Refill Subcutaneous Advanced Consumer Information (Micromedex)
• Sumatriptan Advanced Consumer Information (Micromedex)
• Sumatriptan Nasal, Oral, Subcutaneous Advanced Consumer Information (Micromedex)
• Sumatriptan Subcutaneous Advanced Consumer Information (Micromedex)
• Sumatriptan AHFS DI Monographs (ASHP)
• Sumatriptan Succinate AHFS DI Monographs (ASHP)